ArticleDermatology and therapy2025

Assessing Long-Term Pain Reduction with Secukinumab in Moderate to Severe Hidradenitis Suppurativa: A Post Hoc Analysis of the SUNSHINE and SUNRISE Phase 3 Trials.

John R Ingram et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.